{
    "clinical_study": {
        "@rank": "115856", 
        "arm_group": {
            "arm_group_label": "Corifollitropin alfa+hMG", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the present  study is to examine the level of ovarian response and the\n      pregnancy rates among poor ovarian responders  treated with a novel treatment protocol with\n      150\u03bcg corifollitropin alfa followed by 300IU hMG in a short GnRH agonist protocol."
        }, 
        "brief_title": "Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Infertility", 
            "Poor Ovarian Response"
        ], 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "Corifollitropin alfa reaches maximum concentrations (Cmax), between 25 and 45 h after\n      injection , a time interval which is significantly shorter as compared to treatment with\n      rFSH. The investigators hypothesized that this rapid increase in the serum FSH concentration\n      may  result in a significantly higher exposure of the small antral follicles to constant\n      high levels of FSH during the early follicular phase, securing not only the recruitment of\n      the follicles, but also the continued growth.\n\n      In the current study the investigators examine whether administration of corifollitropin\n      followed by 300IU hMG in a short GnRH agonist protocol may result in acceptable pregnancy\n      rates in poor ovarian responders fulfilling the \"Bologna criteria\""
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients should fulfill the \"Bologna criteria\" for poor ovarian response\n\n        At least two of the following three features must be present:\n\n        i. Advanced maternal age (\u226540 years) or any other risk factor for POR (poor ovarian\n        response); ii. A previous POR (\u22643 oocytes with a conventional stimulation protocol); iii.\n        An abnormal ovarian reserve test (i.e. AFC <7 follicles or AMH <1.1 ng/ml).\n\n        Two episodes of POR after maximal stimulation are sufficient to define a patient as poor\n        responder in the absence of advanced maternal age or abnormal ORT (ovarian reserve test).\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732068", 
            "org_study_id": "2012/082"
        }, 
        "intervention": [
            {
                "arm_group_label": "Corifollitropin alfa+hMG", 
                "description": "Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards", 
                "intervention_name": "Triptorelin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Corifollitropin alfa+hMG", 
                "description": "Corifollitropin alfa 150\u03bcg (single dose) on day 2 or 3 of the cycle", 
                "intervention_name": "Corifollitropin alfa", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Corifollitropin alfa+hMG", 
                "description": "300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering", 
                "intervention_name": "hpHMG", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Triptorelin", 
                "Deslorelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Poor ovarian response", 
            "Poor ovarian responders", 
            "Bologna criteria for poor ovarian response"
        ], 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1090"
                }, 
                "name": "Centre for Reproductive Medicine UZ Brussel"
            }
        }, 
        "location_countries": {
            "country": [
                "Belgium", 
                "Denmark"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study for the Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol", 
        "overall_official": {
            "affiliation": "UZ Brussel", 
            "last_name": "Nikolaos P Polyzos, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Ongoing pregnancy rate", 
            "safety_issue": "No", 
            "time_frame": "10 to 12 weeks of gestation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732068"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitair Ziekenhuis Brussel", 
            "investigator_full_name": "Nikolaos P. Polyzos", 
            "investigator_title": "Principal investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of oocytes retrieved", 
                "safety_issue": "No", 
                "time_frame": "Day of oocyte retrieval"
            }, 
            {
                "measure": "Cycles with embryo transfer", 
                "safety_issue": "No", 
                "time_frame": "Day of Embryo transfer"
            }
        ], 
        "source": "Universitair Ziekenhuis Brussel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitair Ziekenhuis Brussel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}